Sequential neurohumoral measurements in patients with congestive heart failure☆
References (33)
- et al.
Plasma norepinephrine in congestive heart failure
Am J Cardiol
(1978) - et al.
Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure
Am J Cardiol
(1982) - et al.
Endogenous catecholamine levels in chronic heart failure: relation to the severity of hemodynamic abnormalities
Am J Med
(1985) - et al.
The renin system: variations in man measured by radioimmunoassay or bioassay
Kidney Int
(1972) - et al.
Efficacy of captopril in low-renin congestive heart failure: Importance of sustained reactive hyperreninemia in distinguishing responders from non-responders
Am J Cardiol
(1984) - et al.
Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure
Am J Cardiol
(1984) - et al.
Role of the renin-angiotensin system in the development of congestive heart failure in the dog as assessed by chronic converting-enzyme blockade
Am J Cardiol
(1984) - et al.
Angiotensin II levels, hemodynamics, and sympathoadrenal function after low dose captopril in heart failure
Am J Med
(1984) - et al.
Enalapril: a new angiotensinconverting enzyme inhibitor in chronic heart failure: acute and chronic hemodynamic evaluations
J Am Coll Cardiol
(1983) - et al.
Augmented sympathetic neurotransmitter activity in the peripheral vascular bed of patients with congestive heart failure and cardiac norepinephrine depletion
Circulation
(1968)
The neurohumoral axis in congestive heart failure
Ann Intern Med
Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
N Engl J Med
Effects of orthotopic heart transplantation on sympathetic control mechanisms in congestive heart failure
Am J Cardiol
Plasma catecholamines in patients with congestive heart failure
Cardiovasc Rev Rep
Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure
Circulation
Pattern of renal vasoconstriction and transmitter release during sympathetic stimulation in the presence of angiotensin and cocaine
J Pharmacol Exp Ther
Cited by (58)
Atrial ganglionated plexi stimulation may be an effective therapeutic tool for the treatment of heart failure
2013, Medical HypothesesCitation Excerpt :It has been shown in the past decades that neurohumoral activation plays an important role in the pathophysiology of heart failure. The autonomic sympathetic/parasympathetic imbalance, i.e. the activation of sympathetic nervous system and the reduction of parasympathetic activity, constitutes a fundamental element of chronic heart failure pathophysiology [4–7]. It has been shown that the autonomic imbalance is associated with progressive ventricular remodeling, ventricular arrhythmia generation and disease progression [8].
Impact of angiotensin II on skeletal muscle metabolism and function in mice: Contribution of IGF-1, Sirtuin-1 and PGC-1α
2013, Acta HistochemicaCitation Excerpt :Activation of the renin–angiotensin–aldosterone system occurs in the context of both normal cardiovascular aging and numerous cardiovascular diseases, including hypertension and chronic heart failure (CHF). Significant increased concentrations of angiotensin II (Ang-II) in the plasma could be detected in particular in patients with CHF (Cohn et al., 1984; Francis et al., 1988). Another hallmark of patients with CHF is a reduced exercise tolerance accompanied by impaired skeletal muscle function, including impaired contractility (Perreault et al., 1993), enhanced immune activation (Toth et al., 2006), reduced muscle protein synthesis (Toth et al., 2005), and enhanced muscle protein degradation (Tisdale, 2002).
β-blockers for heart failure: Why, which, when, and where
2003, Medical Clinics of North AmericaEndothelial dysfunction in patients with chronic heart failure: Systemic effects of lower-limb exercise training
2001, Journal of the American College of Cardiology
- ☆
Supported by Grants HL 22977, HL 07184, HL 32427, and RR-400 from the National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, Md., and by a Merit Review Grant from the Research Service, Veterans Administration, Washington, D.C.